Related Experiment Video
Updated: Jan 6, 2026

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression
Wout Arras1,2, Baptiste Oosterlinck1,2, Julie Gassman1,2
1Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Background:
The intestinal mucosal barrier plays an important role in the pathophysiology of inflammatory bowel disease (IBD), with mucins being key components of this barrier. Classified as either transmembrane or secreted, these highly glycosylated proteins protect the mucosal barrier while also influencing barrier integrity. Given their indispensable role in maintaining the intestinal mucosal barrier, mucins are compelling candidates for the evaluation of barrier dysfunction. Numerous studies have investigated mucins in the context of IBD, but a clear consensus regarding their expression, polymorphisms, and post-translational modifications is missing. This systematic review summarizes mucin alterations at the transcriptional, translational, and post-translational levels in the presence/absence of intestinal inflammation in IBD patients.
Methods:
To this end, PubMed, Scopus, and Web of Science were searched for studies published between February 1993 and January 2025, yielding 69 articles eligible for inclusion.
Results:
The expression of MUC1, MUC5AC, and MUC6 was reported to be upregulated at both RNA (isoform) and protein level, in contrast to MUC12, which exhibited reduced expression in inflamed mucosa only at RNA isoform level. MUC2 was the only mucin consistently downregulated at the protein level, despite unchanged mRNA expression, whereas polymorphisms of MUC2, MUC3A, MUC4, MUC13, MUC19, MUC21, and MUC22 were associated with susceptibility to Crohn's disease, ulcerative colitis, or IBD in general. Post-translational modifications, such as hypoglycosylation of MUC1 and MUC2, as well as a reduction of mucin sulphation of MUC2 were reported.
Conclusion:
Together, these findings underscore the involvement of mucins in IBD and point to their potential as biomarkers for barrier dysfunction.
More Related Videos
08:51Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
06:31Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...